Oncopeptides: Oncopeptides increases sales while operating loss increased

The research company Oncopeptides reports increased sales while the operating loss increased in the fourth quarter of 2024 compared to the same quarter last year. Net sales increased 86.8 percent to SEK 9.9 million (5.3). Gross profit amounted to SEK 9.2 million (4.6), with a gross margin of 92.9 percent (86.8). The operating result was SEK -83.3 million (-81.0). The result before tax was SEK -82.6 million (-79.1). The result after tax was SEK -83.4 million (-81.2). Earnings per share amounted to SEK -0.39 (-0.90). Cash flow from operating activities amounted to SEK -71.5 million (-55.4) in the fourth quarter. Cash and cash equivalents amounted to SEK 178.5 million (173.4) at year-end. "Oncopeptides' cash position at the end of 2024 amounted to SEK 179 million. Although sales in 2024 did not meet our expectations, this has been compensated by a strengthened cost focus. Our cash position is therefore in line with our forecasts as we enter 2025," the company wrote in the financial statements. - Sales of Pepaxti increased by approximately 35% in the fourth quarter compared to the previous quarter. With the launch in Italy now underway, Oncopeptides is active in all key European markets and we can focus even more on activities to increase sales," says Oncopeptides CEO Sofia Heigis in the financial statements. Sales of Pepaxti in the fourth quarter of 2024 amounted to SEK 9.9 million, compared to SEK 7.4 million in the third quarter of 2024. - "We have also taken other steps towards profitability, including securing a regulatory path forward and partnership discussions for Pepaxti in Japan, as well as positive discussions with the US FDA on our pipeline molecule OPD5," Heigis continues. Oncopeptides, SEKm Q4-2024 Q4-2023 Change in Net sales 9,9 5,3 86,8% Gross profit 9,2 4,6 100,0% Gross margin 92,9% 86,8% Operating profit/loss -83,3 -81,0 Result before tax -82,6 -79,1 Net result -83,4 -81,2 Earnings per share, SEK -0,39 -0,90 Cash flow from operating activities -71,5 -55,4 Cash and cash equivalents 178,5 173,4 2,9%